135 related articles for article (PubMed ID: 2830339)
1. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
[TBL] [Abstract][Full Text] [Related]
2. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors.
Rosato A; Bronte V; Mandruzzato S; Zambon A; Calderazzo F; Biasi G; Zanovello P; Collavo D
Int J Cancer Suppl; 1992; 7():24-7. PubMed ID: 1385341
[TBL] [Abstract][Full Text] [Related]
3. Induction of Moloney murine sarcoma virus tolerance in adult mice by anti-CD4 monoclonal antibody treatment.
Biasi G; Mazzocchi M; Facchinetti A; Panozzo M; Zanovello P; Collavo D; Chieco-Bianchi L
Cancer Res; 1990 Sep; 50(17 Suppl):5703S-5706S. PubMed ID: 2167167
[TBL] [Abstract][Full Text] [Related]
4. Moloney murine leukemia virus tolerance in anti-CD4 monoclonal antibody-treated adult mice.
Biasi G; Facchinetti A; Panozzo M; Zanovello P; Chieco-Bianchi L; Collavo D
J Immunol; 1991 Oct; 147(7):2284-9. PubMed ID: 1833453
[TBL] [Abstract][Full Text] [Related]
5. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
6. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes.
Flyer DC; Burakoff SJ; Faller DV
J Immunol; 1985 Oct; 135(4):2287-92. PubMed ID: 2411792
[TBL] [Abstract][Full Text] [Related]
7. Suppressor T cells regulate the cytolytic T lymphocyte response to syngeneic tumors induced by murine sarcoma virus (MSV) in the mouse.
Plata F; MacDonald HR; Shain B
J Immunol; 1979 Aug; 123(2):852-60. PubMed ID: 156765
[TBL] [Abstract][Full Text] [Related]
8. Temporary inhibition of Moloney-murine sarcoma virus (M-MSV) induced-tumours by adoptive transfer of ricin-treated T-lymphocytes.
Cerundolo V; Zanovello P; McIntosh D; Fabbris R; Davies AJ; Collavo D
Br J Cancer; 1987 Apr; 55(4):413-9. PubMed ID: 2437947
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of recovery from acute virus infection. VIII. Treatment of lymphocytic choriomeningitis virus-infected mice with anti-interferon-gamma monoclonal antibody blocks generation of virus-specific cytotoxic T lymphocytes and virus elimination.
Wille A; Gessner A; Lother H; Lehmann-Grube F
Eur J Immunol; 1989 Jul; 19(7):1283-8. PubMed ID: 2503388
[TBL] [Abstract][Full Text] [Related]
10. Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.
BasombrÃo MA; Mayer AM; Pasqualini CD
Cancer Res; 1977 Jun; 37(6):1768-76. PubMed ID: 192461
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice.
Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H
Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223
[TBL] [Abstract][Full Text] [Related]
12. Immune response to Moloney murine leukemia virus nonviral, tumor-associated antigens fails to provide in vivo tumor protection.
Jiang D; Flyer DC
J Immunol; 1992 Feb; 148(3):974-80. PubMed ID: 1730885
[TBL] [Abstract][Full Text] [Related]
13. Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system.
Plata F; Cerottini JC; Brunner KT
Eur J Immunol; 1975 Apr; 5(4):227-33. PubMed ID: 185057
[TBL] [Abstract][Full Text] [Related]
14. Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV) induced tumors. I. Physical properties of cytolytic T lymphocytes generated in vitro and of their immediate progenitors.
Plata R; MacDonald HR; Engers HD
J Immunol; 1976 Jul; 117(1):52-8. PubMed ID: 180182
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
Wood GW
Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
[TBL] [Abstract][Full Text] [Related]
16. Tumor inhibiting capacity of spleen and lymph node cells from mice with murine sarcoma virus (MSV-M)-induced tumors.
Weiland E; Mussgay M
Z Immunitatsforsch Exp Klin Immunol; 1975 Nov; 150(5):414-23. PubMed ID: 181922
[TBL] [Abstract][Full Text] [Related]
17. The effect of interferon treatment of targets on susceptibility to cytotoxic T-lymphocyte killing: augmentation of allogeneic killing and virus-specific killing relative to viral antigen expression.
Blackman MJ; Morris AG
Immunology; 1985 Nov; 56(3):451-7. PubMed ID: 2416676
[TBL] [Abstract][Full Text] [Related]
18. Interferon-induced inhibition of Moloney sarcoma virus-transformed cells: requirement for T-cells.
Skicki-Mullen MB; Markovic SN; Murasko DM
Cancer Res; 1989 Feb; 49(3):522-7. PubMed ID: 2463077
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting passive monoclonal antibody therapy of Moloney sarcoma in BALB/c mice.
Kennel SJ; Lankford PK; Flynn KM; Winegar R
Cancer Res; 1985 Aug; 45(8):3782-9. PubMed ID: 2410101
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Shu S; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2895-903. PubMed ID: 2411817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
